CLINICAL IMMUNOLOGY
A study on FoxP3 and Tregs in paired samples of peripheral blood and synovium in rheumatoid arthritis
More details
Hide details
Submission date: 2015-03-27
Final revision date: 2015-06-09
Acceptance date: 2015-06-09
Publication date: 2016-01-15
Cent Eur J Immunol 2015;40(4):431-436
KEYWORDS
ABSTRACT
There is an increasing evidence suggesting the role of fork head boxP3 (FoxP3) in the development and the regulation of CD4+CD25+ Treg cells. T-cell regulatory mechanisms in rheumatoid arthritis patients were evaluated by the contributing factors such as pro-inflammatory cytokines, circulating immune complexes, HLA DR expression, ligand binding biomarkers, FoxP3 expression in paired samples of peripheral blood (PB) and synovial fluid (SF). These cellular responses were further correlated with the humoral immune responses such as anti-cyclic citrullinated peptides IgG (CCP), circulating immune complex-c1q IgG (CIC), immunoglobulin G (IgG) and immunoglobulin M (IgM) of the rheumatoid arthritis factor (RAF). The results suggest a definitive role of Tregs in the homeostatic control because there is an increase in FoxP3 (37%) and HLA-DR (45%) expression in the synovial fluid as compared to PB. Furthermore, humoral responses as a downstream effector mechanism are positively correlated with the pathogenesis of rheumatoid arthritis (RA). A positive relationship exists between quantitative anti-CCP production and the expression of HLA-DR. The study relates an increased and pivotal role of B cell activation in the synovial fluid thereby permitting the need to ablate the targeted B cell immune responses.
REFERENCES (20)
1.
Kourilovitch M, Maldonado CG, Prado EO (2014): Diagnosis and classification of rheumatoid arthritis. J Autoimmun 48: 26-30.
2.
Boissier MC, Semerano L, Challal S, et al. (2012):Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 39: 222-228.
3.
Van Venrooij WJ, Van Beers JJ, Pruijn GJ (2008): Anti-CCP antibody a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 1143: 268-285.
4.
Agarwal S, Misra R, Agarwal A (2007): Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheum 26: 201-204.
5.
Yeo L, Toellner KM, Salmon M, et al. (2011): Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Annals of the Rheumatic Diseases 70: 2022-2028.
6.
Hong N, Yingxia Z, Runsheng L, et al. (2013): Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF- in rheumatoid arthritis. Nat Med 19: 322-328.
7.
Bugatti S, Vitolo B, Caporali R (2014): B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers. BioMed Research International 681678: 14 pages.
8.
Leipe J, Skapenko A, Lipsky PE, KoopsHS (2005): Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther 7: 93-99.
9.
Aletaha D, Neogi T, Silman AJ, et al (2010): Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 62: 2569-2581.
10.
De Clerck LS (1995): B lymphocytes and humoral immune responses in rheumatoid arthritis. Clin Rheumatol Suppl 14: 14-18.
11.
Kapitany A, Szabo Z, Lakos G, et al. (2008) : Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis. Isr Med Assoc J 2008; 10: 32-36.
12.
Forslind K, Ahlmén M, Eberhardt K, et al. (2004): Prediction of radiological outcome in early rheumatoid arthritis in a clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090-1095.
13.
Van Gaalen FA, Aken JV, Huizinga TW, et al. (2004): Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50: 2113-2121.
14.
Irigoyen P, Lee AT, Wener MH, et al. (2005): Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 52: 3813-3818.
15.
Hill JA, Southwood S, Sette A, Jevnikar AM, et al. (2003): The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLADRB1* 0401 MHC class II molecule. J Immunol 171: 538-541.
16.
Shoenfeld Y, Isenberg DA (1989): The mosaic of autoimmunity. Immunol Today 10: 123-126.
17.
Worrall JG, Snaith ML, Batchelor JR, Isenberg DA (1990): SLE: a rheumatological view analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. Q J Med 74: 319-330.
18.
Cao D, Malmström V, Allan CB, et al. (2003): Isolation and functional characterization of regulatory CD25 bright CD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 33: 215-223.
19.
Bromberg J (2013): TNF- trips up Treg cells in rheumatoid arthritis, Nat Med 19: 269-270.
20.
Brennan FM, McInnes IB (2008): Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545.